about
Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemiaThe Akt pathway regulates survival and homing in Waldenstrom macroglobulinemiaTargeting NF-kappaB in Waldenstrom macroglobulinemiaReview of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patientsPhase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemiaResults of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.New Therapeutic Approaches for Waldenstrom MacroglobulinemiaNovel agents in Waldenström macroglobulinemia.Novel agents in Waldenstrom Macroglobulinemia.Pulmonary vascular resistance and viscosity: the forgotten factor.Targeting the bone marrow in Waldenstrom macroglobulinemia.The bone marrow microenvironment in waldenstrom macroglobulinemia.Novel treatment options for Waldenström macroglobulinemiaWaldenström macroglobulinemia: from biology to treatment.Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia.The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study.Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemia
P2860
Q24634360-94EC848C-003B-4A8A-8F22-2650F7D1FFF6Q28244041-2829E378-14BE-4F2A-980A-365E8A1BDA0BQ28272373-B64BD5A7-9B78-402D-A7E4-CD63A77C4BEFQ28291793-CA52F45C-A766-401D-9940-993598C9328EQ33388196-167C108A-43E3-46A3-8321-EEE2AFEBABC6Q33405096-A9A66C1D-07F8-4A7F-8DA9-5430A5D4FD9BQ33414529-DAA0ED00-9F6C-4D63-94CF-76A50DB4069FQ33711127-507C2421-1B31-4F9E-9D80-68FA10DD1D67Q35176177-FA8110EB-2208-46D7-B609-D497B1A3145DQ35429544-4B6644C5-2469-40A7-BFF3-1C87EDB11B7BQ36117791-AD5827D4-A8C6-4B1C-BB50-415A5A9D1A3BQ37856936-DDF85DC9-A15E-4E96-8B29-93D118E548F7Q37950586-BB5BC2DC-CA36-4E2E-B0A1-64D89C7FFD62Q38095959-EB15E306-231D-4CC3-9B3A-F59ED13E0C3FQ38167433-D6B760A3-AC85-4911-875D-294C01D66C66Q38176969-3EAD08A2-7120-499D-924E-DFAE637D53D6Q39044362-A26A517D-C677-4C68-950A-7BFE61B31BD0Q39738249-50DC9C9B-3BDA-4752-AFC4-B667F49010E0Q47593550-3086C115-2062-47D5-9859-5ADD9CF8E897Q57904151-FC881AD0-C0AA-48F6-BA51-4959703315D8
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Waldenström macroglobulinemia
@ast
Waldenström macroglobulinemia
@en
Waldenström macroglobulinemia
@nl
type
label
Waldenström macroglobulinemia
@ast
Waldenström macroglobulinemia
@en
Waldenström macroglobulinemia
@nl
prefLabel
Waldenström macroglobulinemia
@ast
Waldenström macroglobulinemia
@en
Waldenström macroglobulinemia
@nl
P2860
P1476
Waldenström macroglobulinemia
@en
P2093
Irene M Ghobrial
Thomas E Witzig
P2860
P2888
P304
P356
10.1007/S11864-004-0015-5
P407
P577
2004-06-01T00:00:00Z
P5875
P6179
1009803290